SOPH’s AI-genomics engine: a small-cap data play growing up

The thesis

SOPHiA GENETICS (SOPH) is a healthcare tech company that uses artificial intelligence to help doctors and drug makers read complex genetic and medical data.[4][6] Business momentum is clearly picking up: Q1 2026 revenue hit $21.7 million, up 22% versus last year, with strong gross margins around 68% and improving operating losses.[1] The company says full‑year 2026 sales should land between $92–94 million, again about 20–22% growth.[1] They’ve expanded with existing hospital and lab customers, signing three European deals each worth over $1 million a year.[1] On June 16, 2026, SOPH raised about $50–57.5 million by selling roughly 10.5–12.1 million new shares at $4.75, giving them fresh cash to fund growth.[3][4][10]

Everyone wishes they'd bought Nvidia early. Here's how to spot the next one.

The biggest winners of the last decade had one thing in common. Our data follows those exact moves — and turns them into 10 names to watch right now.

The big names in the AI, Space, Nuclear and Robotics race. The window to get in early is closing fast. Don't wait.

See the top 10 stocks now — free ›

💡 Why this matters

If you believe medicine is becoming more data‑driven, SOPH sits right in that lane. They sell a cloud platform, SOPHiA DDM, that helps hundreds of hospitals and labs turn DNA and scan data into treatment decisions for cancer and rare diseases.[4][6] That same platform is starting to be used by drug companies to design and test new medicines more efficiently.[1][6] In plain terms, SOPH is trying to be part of the “AI for healthcare” backbone, a trend that could reshape how quickly patients get the right drugs and care.[4][6]

▲ Catalysts

+ Q1 2026 delivered 22% revenue growth to $21.7M, with net dollar retention rising to 117%, showing existing customers are spending more.[1]
+ Three new European expansion deals, each over $1M per year, deepen SOPHiA DDM’s footprint in major hospital and lab customers.[1]
+ Fresh capital from June 16, 2026 share offering: about $50–57.5M raised at $4.75 per share to fund platform and sales expansion.[3][4][10]
+ Guidance for 2026: revenue $92–94M and smaller operating‑style losses (adjusted EBITDA loss $29–32M), showing a path toward better margins.[1]
+ Growing BioPharma projects where drug companies pay SOPH to help with evidence generation and potential companion diagnostic tools.[1]

▼ Risks

! The company still loses money, with a Q1 2026 net loss of $19.3M and ongoing negative operating cash metrics.[1]
! June 2026 share sale added roughly 10.5–12.1M new shares, meaning existing owners now own a smaller slice of the pie.[3][4][10]
! Hospitals, labs, and drug makers can be slow, cautious buyers; big contracts take time and may not ramp as fast as hoped.[1]
! Competition from larger health‑tech and genomics players could squeeze pricing and make it harder for SOPH to stand out.[6]

🎯 One thing to take away

SOPHiA GENETICS (SOPH) is a small healthcare tech company trying to become a key “AI brain” for hospitals and drug makers. Its software helps turn DNA tests, scans, and medical records into practical treatment ideas, especially for cancer and rare diseases.[4][6] The numbers are heading in the right direction: sales are growing more than 20% a year and existing customers are spending more.[1] On the flip side, SOPH still loses money and just sold a big batch of new shares in June 2026, which shrinks each existing slice of the company.[3][10] If you’re curious about the AI‑plus‑genomics story and can tolerate early‑stage risk, SOPH is a name that may be worth watching, not ignoring.

Data sources & methodology

All figures derive from official, public-domain government filings. Read our methodology for how we collect, process and score this data. See the methodology →

TZ Researched & published by TradesZ Research

Want our premium picks too?

Pro subscribers get our strongest pre-pop ideas + real-time buy-zone alerts.

Thinking about SOPH?

Our data likes 10 other stocks even more right now — under-the-radar names we believe have monster upside potential. Get the free list before the crowd catches on.

Show me the 10 stocks — free →

Free · no credit card · unsubscribe in one click

Not investment advice. We share research and analyses for educational purposes. Investing in stocks involves risk, including possible loss of capital. Always do your own research.